A first-in-human trial of GBR 310 in healthy adult volunteers
Phase of Trial: Phase I
Latest Information Update: 25 Jul 2018
Price : $35 *
At a glance
- Drugs Omalizumab (Primary)
- Indications Allergic asthma; Urticaria
- Focus First in man; Pharmacokinetics
- Sponsors Glenmark Pharmaceuticals Ltd
- 25 Jul 2018 According to a Glenmark Pharmaceuticals Ltd. media release, the company announced encouraging results from this study.
- 25 Jul 2018 Status changed to completed.
- 03 May 2017 New trial record